Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 as Second-Line Therapy for Pediatric Primary Immune Thrombocytopenia
ChiCTR2400091685Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in immune thrombocytopenia (ITP), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Complete response rate at 1 month. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ChiCTR2400091685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091685.